Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.

endometrial cancer monocyte-to-lymphocyte ratio neutrophil-to-lymphocyte ratio platelet−to−lymphocyte ratio prognosis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 01 07 2021
accepted: 31 03 2022
entrez: 2 6 2022
pubmed: 3 6 2022
medline: 3 6 2022
Statut: epublish

Résumé

Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), or monocyte-lymphocyte ratio (MLR) has been shown to be related to the poor prognosis of cervical cancer, ovarian cancer, breast cancer, and other malignant tumors, but their role in predicting the prognosis of endometrial cancer is still controversial. Therefore, we conducted this meta-analysis to evaluate the effectiveness of NLR more accurately, PLR, or MLR in predicting the prognosis of endometrial cancer (EC). This review systematically searched for relevant publications in databases of the Cochrane Library, PubMed, EMBASE, CNKI, WanFang, VIP, and CBM. Pooled hazard ratios (HR) with 95% confidence intervals (95% CI) were determined and used to explore the association between inflammatory biomarkers (NLR, PLR, and MLR) and overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in a random-effects model. We also conducted subgroup analysis and publication bias in this meta-analysis. Stata 12.0 was used for statistical analysis. This meta-analysis contained 14 eligible studies including 5,274 patients. Our results showed that NLR or PLR was associated with OS [NLR: HR, 2.51; 95% CI, 1.70-3.71; Our results indicated that pretreatment NLR and PLR were biomarkers of poor prognosis in patients with endometrial cancer. The results indicated that NLR or PLR was associated with OS and disease-free survival DFS, and NLR was associated with PFS only in univariate analysis, but MLR was not associated with OS or DFS.

Identifiants

pubmed: 35651788
doi: 10.3389/fonc.2022.734948
pmc: PMC9149577
doi:

Types de publication

Systematic Review

Langues

eng

Pagination

734948

Informations de copyright

Copyright © 2022 Leng, Wu and Zhang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Oncol. 1999 Oct;15(4):781-6
pubmed: 10493962
Oncology. 2019;96(5):259-267
pubmed: 30893700
Arch Gynecol Obstet. 2020 Jan;301(1):251-261
pubmed: 31768743
Gynecol Oncol. 2006 Jun;101(3):520-9
pubmed: 16556457
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
Gynecol Oncol. 1998 Aug;70(2):210-4
pubmed: 9740692
Int J Gynaecol Obstet. 2017 Sep;138(3):311-319
pubmed: 28599056
PLoS One. 2015 Jun 24;10(6):e0130640
pubmed: 26107255
J Clin Med. 2020 May 12;9(5):
pubmed: 32408668
Anticancer Res. 2015 Jan;35(1):337-43
pubmed: 25550569
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
J Obstet Gynaecol Res. 2015 Mar;41(3):445-8
pubmed: 25363740
Acta Oncol. 2021 Jun;60(6):704-713
pubmed: 33586577
Anticancer Res. 2011 Sep;31(9):2995-8
pubmed: 21868550
Am J Surg. 2010 Aug;200(2):197-203
pubmed: 20122680
Cancer Immunol Immunother. 2009 Jan;58(1):15-23
pubmed: 18414853
J Surg Oncol. 2008 May 1;97(6):513-8
pubmed: 18335453
PLoS One. 2014 Jun 26;9(6):e101119
pubmed: 24968121
J Turk Ger Gynecol Assoc. 2018 Jun 04;19(2):78-86
pubmed: 29882397
Gynecol Oncol. 2015 Apr;137(1):112-8
pubmed: 25680864
J Obstet Gynaecol. 2019 Feb;39(2):237-241
pubmed: 30370797
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Feb;51(2):112-6
pubmed: 26898867
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7
pubmed: 16364998
Asian Pac J Cancer Prev. 2014;15(4):1689-92
pubmed: 24641391
Br J Cancer. 2015 Jul 14;113(2):311-20
pubmed: 26079303
Am J Obstet Gynecol. 2021 May;224(5):506.e1-506.e8
pubmed: 33127429
Ann Surg Oncol. 2012 Jan;19(1):217-24
pubmed: 21638095
Biomarkers. 2012 May;17(3):216-22
pubmed: 22424597
J Cancer. 2016 Feb 20;7(5):538-45
pubmed: 27053952
Gastric Cancer. 2010 Aug;13(3):170-6
pubmed: 20820986
Eur J Obstet Gynecol Reprod Biol. 2018 Jul;226:25-29
pubmed: 29804024
BMC Cancer. 2020 May 24;20(1):464
pubmed: 32448185

Auteurs

Jiali Leng (J)

Division of Obstetrics and Gynecology, The Second Hospital of Jilin University, Jilin University, Changchun, China.

Fei Wu (F)

Division of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, China.

Lihui Zhang (L)

Division of Obstetrics and Gynecology, The Second Hospital of Jilin University, Changchun, China.

Classifications MeSH